DCC-3116

DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, in combination with the KIT inhibitor ripretinib induces complete regressions in GIST preclinical models.

Presentation of New Preclinical Data Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023.

DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with encorafenib and cetuximab in BRAF V600E mutant colorectal cancer models.

Presentation of New Clinical Study Results from DCC-3116 and Vimseltinib at the European Society for Medical Oncology (ESMO) Congress 2022.

Initial monotherapy results of a phase 1 first‑in‑human study of ULK1/2 inhibitor DCC‑3116 alone and in combination with MAPK pathway inhibition.

DCC -3116 Overview and Preclinical Data.

DCC-3116, a First-in-Class Selective Inhibitor Of ULK1/2 Kinases and Autophagy, Combines with the KRASG12C Inhibitor Sotorasib Resulting in Tumor Regression in NSCLC Xenograft Models.

DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with EGFR inhibitors osimertinib and afatinib in NSCLC preclinical models.

Discovery of ULK1/2 inhibitor DCC 3116 for treatment of RAS driven cancers.

Preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers. 

DCC-3116: A Selective ULK Kinase Inhibitor; Potential First-in-Class Autophagy Inhibitor to Treat Mutant RAS Cancers